GLP-1 Drug Effectiveness Reduced by Genetic Variants
Key Points Summary Genetic variants in the PAM enzyme may reduce response to GLP-1 receptor agonists Around 10% of individuals
Read MoreKey Points Summary Genetic variants in the PAM enzyme may reduce response to GLP-1 receptor agonists Around 10% of individuals
Read MoreAccording to recent studies, people with diabetes may benefit further from the combination use of glucagon-like peptide-1 receptor agonists (GLP1-RAs)
Read MoreIsozymes, which perform functions similar to those of human enzymes but have different structures, are produced by the gut microbiota,
Read More